Kiniksa Pharmaceuticals International, plc
KNSA
Pozycja w akcjach
#2931
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Cena akcji
$80.10
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$6.25B
Zmiana (1 dzień)
-3.69%
Zmiana (1 rok)
105.92%
Kraj
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategoria
Healthcare
Historia ceny akcji dla Kiniksa Pharmaceuticals International, plc (KNSA)
Najwyższa cena zamknięcia: $78.59 dnia 2026-10-01
Najniższa cena zamknięcia: $18.08 dnia 2018-05-01
Najniższa cena zamknięcia: $18.08 dnia 2018-05-01
Historia cen akcji firmy Kiniksa Pharmaceuticals International, plc od 2018 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 31.83% |
| 2025 | 101.55% |
| 2024 | 16.14% |
| 2023 | 13.98% |
| 2022 | 22.63% |
| 2021 | -31.53% |
| 2020 | 57.49% |
| 2019 | -47.95% |
| 2018 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $46.29 | 37.83% |
SE
|
|
| $171.04 | 23.67% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
